General Information of the Protein
Protein ID
PT01500
Protein Name
Heat shock protein HSP 90-alpha
Secondarily
Protein Name
Heat shock 86 kDa
Lipopolysaccharide-associated protein 2
Renal carcinoma antigen NY-REN-38
Gene Name
HSP90AA1
Secondarily
Gene Name
HSP90A
HSPC1
HSPCA
Sequence
MPEETQTQDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAEEKEDKEEEKEKEEKESEDKPEIEDVGSDEEEEKKDGDKKKKKKIKEKYIDQEELNKTKPIWTRNPDDITNEEYGEFYKSLTNDWEDHLAVKHFSVEGQLEFRALLFVPRRAPFDLFENRKKKNNIKLYVRRVFIMDNCEELIPEYLNFIRGVVDSEDLPLNISREMLQQSKILKVIRKNLVKKCLELFTELAEDKENYKKFYEQFSKNIKLGIHEDSQNRKKLSELLRYYTSASGDEMVSLKDYCTRMKENQKHIYYITGETKDQVANSAFVERLRKHGLEVIYMIEPIDEYCVQQLKEFEGKTLVSVTKEGLELPEDEEEKKKQEEKKTKFENLCKIMKDILEKKVEKVVVSNRLVTSPCCIVTSTYGWTANMERIMKAQALRDNSTMGYMAAKKHLEINPDHSIIETLRQKAEADKNDKSVKDLVILLYETALLSSGFSLEDPQTHANRIYRMIKLGLGIDEDDPTADDTSAAVTEEMPPLEGDDDTSRMEEVD
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Other cytosolic protein
Function
Molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved for instance in cell cycle control and signal transduction. Undergoes a functional cycle that is linked to its ATPase activity which is essential for its chaperone activity. This cycle probably induces conformational changes in the client proteins, thereby causing their activation. Interacts dynamically with various co-chaperones that modulate its substrate recognition, ATPase cycle and chaperone function (PubMed:11274138, PubMed:15577939, PubMed:15937123, PubMed:27353360, PubMed:29127155, PubMed:12526792). Engages with a range of client protein classes via its interaction with various co-chaperone proteins or complexes, that act as adapters, simultaneously able to interact with the specific client and the central chaperone itself (PubMed:29127155). Recruitment of ATP and co-chaperone followed by client protein forms a functional chaperone. After the completion of the chaperoning process, properly folded client protein and co-chaperone leave HSP90 in an ADP-bound partially open conformation and finally, ADP is released from HSP90 which acquires an open conformation for the next cycle (PubMed:27295069, PubMed:26991466). Plays a critical role in mitochondrial import, delivers preproteins to the mitochondrial import receptor TOMM70 (PubMed:12526792). Apart from its chaperone activity, it also plays a role in the regulation of the transcription machinery. HSP90 and its co-chaperones modulate transcription at least at three different levels (PubMed:25973397). In the first place, they alter the steady-state levels of certain transcription factors in response to various physiological cues(PubMed:25973397). Second, they modulate the activity of certain epigenetic modifiers, such as histone deacetylases or DNA methyl transferases, and thereby respond to the change in the environment (PubMed:25973397). Third, they participate in the eviction of histones from the promoter region of certain genes and thereby turn on gene expression (PubMed:25973397). Binds bacterial lipopolysaccharide (LPS) and mediates LPS-induced inflammatory response, including TNF secretion by monocytes (PubMed:11276205). Antagonizes STUB1-mediated inhibition of TGF-beta signaling via inhibition of STUB1-mediated SMAD3 ubiquitination and degradation (PubMed:24613385). Mediates the association of TOMM70 with IRF3 or TBK1 in mitochondrial outer membrane which promotes host antiviral response (PubMed:20628368, PubMed:25609812).
    Show/Hide
Uniprot ID
Primary ID:
P07900

Secondarily ID:
A8K500
B3KPJ9
Q2PP14
Q5CAQ6
Q5CAQ7
Q9BVQ5
    Show/Hide
Ensembl ID
ENSG00000080824
HGNC ID
HGNC:5253
Subcellular Location
Nucleus
Cytoplasm
Melanosome
Cell membrane
Mitochondrion
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein

Protein
Cell Line
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000695 , CHL
Compound ID Compound Name Compound Formula
CP0367635
8-(2-Chloro-5-methoxy-phenylsulfanyl)-9-pent-4-ynyl-9H-purin-6-ylamine
   Show/Hide
C17H16ClN5OS
 1
1
EC50 = 9600 nM
   TI
   LI
   LO
   TS
CP0083379
8-(6-Bromo-benzo[1,3]dioxol-5-ylsulfanyl)-9-pent-4-ynyl-9H-purin-6-ylamine
   Show/Hide
C17H14BrN5O2S
 1
1
EC50 = 14700 nM
   TI
   LI
   LO
   TS
CP0167758
8-(2-Bromo-5-methoxy-phenylsulfanyl)-9-pent-4-ynyl-9H-purin-6-ylamine
   Show/Hide
C17H16BrN5OS
 1
1
EC50 = 27600 nM
   TI
   LI
   LO
   TS
CP0215840
8-Sulfanyladenine
   Show/Hide
C17H16IN5OS
 1
1
EC50 = 29700 nM
   TI
   LI
   LO
   TS
CP0041047
8-(2-Chloro-3,4,5-trimethoxy-phenylsulfanyl)-2-fluoro-9-(2-isopropoxy-ethyl)-9H-purin-6-ylamine
   Show/Hide
C19H23ClFN5O4S
 1
1
EC50 > 75000 nM
   TI
   LI
   LO
   TS
CP0167757
8-(2,5-Dimethoxy-phenylsulfanyl)-9-pent-4-ynyl-9H-purin-6-ylamine
   Show/Hide
C18H19N5O2S
 1
1
EC50 > 75000 nM
   TI
   LI
   LO
   TS
CP0178953
8-(2-Chloro-3,4,5-trimethoxy-phenylsulfanyl)-9-pent-4-ynyl-9H-purin-6-ylamine
   Show/Hide
C19H20ClN5O3S
 1
1
EC50 > 75000 nM
   TI
   LI
   LO
   TS
Biochemical Assays
Compound ID Compound Name Compound Formula
CP0054776
BMS-722782
   Show/Hide
C31H43N3O8
 20
1 EC50 = 64.9 nM
2 EC50 = 1000 nM
3 GI50 = 32 nM
4 IC50 = 20 nM
5 IC50 = 46 nM
6 IC50 = 56 nM
7 IC50 = 140 nM
8 IC50 = 309 nM
9 IC50 = 780 nM
10 IC50 = 1190 nM
11 IC50 = 1270 nM
12 IC50 = 9800 nM
13 Kd = 160 nM
14 Kd = 220 nM
15 Kd = 310 nM
16 Kd = 326 nM
17 Kd = 388 nM
18 Kd = 760 nM
19 Ki = 4.6 nM
20 Ki = 29 nM
CP0444104
8-(2-chloro-3,4,5-trimethoxybenzyl)-2-fluoro-9-pent-4-ynyl-9H-purin-6-amine
   Show/Hide
C20H21ClFN5O3
 1
1 EC50 = 1200 nM
CP0036286
5-[2,4-dihydroxy-5-(propan-2-yl)phenyl]-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]-1,2-oxazole-3-carboxamide
   Show/Hide
C26H31N3O5
 9
1 IC50 < 0.4 nM
2 IC50 = 7.8 nM
3 IC50 = 12 nM
4 IC50 = 20 nM
5 IC50 = 22 nM
6 IC50 = 25 nM
7 IC50 = 59 nM
8 IC50 = 61 nM
9 Ki = 9 nM
CP0144005
3-[2-amino-4-chloro-7-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]pyrrolo[2,3-d]pyrimidin-5-yl]prop-2-yn-1-ol
   Show/Hide
C18H18ClN5O2
 1
1 IC50 = 0.7 nM
CP0204312
4-chloro-5-ethynyl-7-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]pyrrolo[2,3-d]pyrimidin-2-amine
   Show/Hide
C17H16ClN5O
 1
1 IC50 = 1 nM
CP0247725
5-[2-amino-4-chloro-7-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]pyrrolo[2,3-d]pyrimidin-5-yl]-2-methylpent-4-yn-2-ol
   Show/Hide
C21H24ClN5O2
 2
1 IC50 = 1.1 nM
2 Ki = 0.2 nM
CP0301980
4-[2-amino-4-chloro-7-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]pyrrolo[2,3-d]pyrimidin-5-yl]but-3-yn-1-ol
   Show/Hide
C19H20ClN5O2
 1
1 IC50 = 2 nM
CP0057361
4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-5,7-dihydroindazol-1-yl]-2-[(4-hydroxycyclohexyl)amino]benzamide
   Show/Hide
C23H27F3N4O3
 4
1 IC50 = 3 nM
2 IC50 = 6 nM
3 IC50 = 29 nM
4 Kd = 4 nM
CP0204311
3-[2-amino-4-chloro-7-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]pyrrolo[2,3-d]pyrimidin-5-yl]propan-1-ol
   Show/Hide
C18H22ClN5O2
 1
1 IC50 = 3.9 nM
CP0060369
2-amino-6-halopurine analogue, 20
   Show/Hide
C14H15ClN6O
 6
1 IC50 = 5.1 nM
2 IC50 = 19 nM
3 IC50 = 29 nM
4 IC50 = 52 nM
5 IC50 = 65.7 nM
6 Ki = 1.7 nM
CP0270352
4-chloro-7-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-5-phenylpyrrolo[2,3-d]pyrimidin-2-amine
   Show/Hide
C21H20ClN5O
 1
1 IC50 = 6 nM
CP0042181
CHEBI:5292
   Show/Hide
C29H40N2O9
 11
1 IC50 = 14 nM
2 IC50 = 20 nM
3 IC50 = 27 nM
4 IC50 = 28 nM
5 IC50 = 40 nM
6 IC50 = 100 nM
7 IC50 = 140 nM
8 IC50 = 272 nM
9 IC50 = 780 nM
10 Kd = 775 nM
11 Kd = 1215 nM
CP0230835
3-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-(4-methoxyphenyl)-1H-pyrazole-5-carboxamide
   Show/Hide
C19H18ClN3O4
 4
1 IC50 = 19 nM
2 IC50 = 25 nM
3 IC50 = 880 nM
4 Kd = 10.7 nM
CP0291803
N-[[1-(5-chloro-2,4-dihydroxyphenyl)-2-oxo-3H-benzimidazol-5-yl]methyl]naphthalene-1-sulfonamide
   Show/Hide
C24H18ClN3O5S
 2
1 IC50 = 30 nM
2 IC50 = 550 nM
Clinical Information about the Protein
Target 1 ( Heat shock protein 90 alpha (HSP90A) )
Target Type Successful Target
Disease 8 Target-related Diseases  8
1 Respiratory tract inflammation [ICD-11: CA07]
2 Asthma [ICD-11: CA23]
3 Breast cancer [ICD-11: 2C60-2C65]
4 Multiple myeloma [ICD-11: 2A83]
5 Melanoma [ICD-11: 2C30]
6 Solid tumour/cancer [ICD-11: 2A00-2F9Z]
7 Peripheral nerve damage [ICD-11: ND56.4]
8 Gastric adenocarcinoma [ICD-11: 2B72]
Approved Drug(s) 2 Approved Drugs  2
1 Amlexanox Approved
Respiratory tract inflammation
2 Cromoglicate Approved
Asthma
Clinical Trial Drug(s) 7 Clinical Trial Drugs  7
1 BIIB-021 Phase 2
Breast cancer
2 NVP-AUY922 Phase 2
Multiple myeloma
3 VER 50589 Phase 2
Breast cancer
4 AT13387 Phase 1
Melanoma
5 Debio 0932 Phase 1
Solid tumour/cancer
6 PU3 Phase 1
Solid tumour/cancer
7 Tanespimycin Phase 2
Breast cancer
Discontinued Drug(s) 2 Discontinued Drugs  2
1 Geldanamycin Discontinued in Phase 2
Peripheral nerve damage
2 IPI-493 Discontinued in Phase 1
Gastric adenocarcinoma
Preclinical Drug(s) 1 Preclinical Drug  1
1 CCT-018159 Preclinical
Solid tumour/cancer